Stefanie Meredith, DO
Family Medicine · Mustang, OKNPI 1740577279
Payments from drug & device makers
Across 401 payments — averaging $13.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$695
- Pfizer$439
- Novo Nordisk$422
- AstraZeneca$340
- Otsuka America Pharmaceutical, Inc.$302
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,395100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 128 | $1,362 |
| Lilly USA, LLC | 58 | $695 |
| Pfizer | 36 | $439 |
| Novo Nordisk | 29 | $422 |
| AstraZeneca | 23 | $340 |
| Otsuka America Pharmaceutical, Inc. | 13 | $302 |
| Boehringer Ingelheim | 11 | $239 |
| GSK | 15 | $210 |
| Merck | 12 | $174 |
| Medtronic | 5 | $152 |
| Supernus Pharmaceuticals, Inc. | 7 | $139 |
| Astellas Pharma US Inc | 9 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $117 |
| Bayer | 5 | $72 |
| Dexcom, Inc. | 4 | $61 |
| Antares Pharma, Inc. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $44 |
| Johnson & Johnson | 3 | $43 |
| Novartis | 2 | $41 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Lundbeck LLC | 2 | $33 |
| Eisai Inc. | 2 | $33 |
| Organon | 2 | $27 |
| Nalpropion Pharmaceuticals LLC | 2 | $26 |
| Clarus Therapeutics Inc. | 2 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Abbott | 1 | $16 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Pacira Therapeutics, Inc. | 1 | $15 |
How this compares
$5,412 in reported general payments places this provider in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 260 | $333,305 |
| EliquisApixaban | 70 | $66,114 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $62,222 |
| RybelsusSemaglutide | 28 | $47,764 |
| OzempicSemaglutide | 37 | $45,843 |
| MyrbetriqMirabegron | 25 | $30,026 |
| QuliptaAtogepant | 21 | $29,288 |
| JardianceEmpagliflozin | 20 | $28,109 |
| FarxigaDapagliflozin Propanediol | 15 | $19,684 |
| LinzessLinaclotide | 11 | $16,123 |
| TrulicityDulaglutide | 12 | $14,231 |
| Bydureon BciseExenatide Microspheres | 13 | $10,791 |
| Mesalamine | 13 | $10,313 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $4,661 |
| Atorvastatin Calcium | 350 | $4,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $695 | $347,535272 claims |
| Novo NordiskRybelsus, Ozempic | $422 | $93,60765 claims |
| PfizerEliquis | $439 | $66,11470 claims |
| GSKTrelegy Ellipta | $210 | $62,22255 claims |
| AbbVieQulipta, Linzess, Synthroid | $1,362 | $47,06854 claims |
| Astellas Pharma US IncMyrbetriq | $137 | $30,02625 claims |
| Boehringer IngelheimJardiance | $239 | $28,10920 claims |
| AstraZenecaFarxiga | $340 | $19,68415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Mustang
- Richard LowranceMustang$758K
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.